2007 DEA Patients 
NORML
JANUARY 17, 2019
As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. Click here to send a message to your federal lawmaker and urge them to support the measure. .
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
Weedistry
MARCH 7, 2019
Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies. A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings.
Meadow
JULY 13, 2018
Back in 2007, it said we don’t want anymore cannabis businesses and despite a general prohibition, we still had more cannabis businesses than any other location. Certain communities have experienced those impacts very differently so patients have experienced impacts differently. It’s every square inch of it.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].
Cannabis Law Report
MARCH 25, 2019
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. 2003, 2004, 2007, 2008, Nov. 6059, 6074, 6075, 6077(a), (b), 6253, Nov.
Expert insights. Personalized for you.
230 
Let's personalize your content